Irbesartan + Hidroclorotiazida Tolife (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is an antihypertensive combination that lowers elevated blood pressure through dual mechanisms.

• Essential hypertension: reduces systolic and diastolic pressure to target levels.
• Hypertension with fluid retention: adds diuretic effect to improve volume control.
• Hypertension requiring combination therapy: provides both ARB and thiazide actions in a single tablet.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. The combined actions result in reduced peripheral resistance and lower blood pressure.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Acute kidney injury or worsening renal function
• Significant drop in blood pressure (hypotension)
• Allergic reactions such as rash or angioedema
• Elevated blood urea nitrogen or creatinine levels
• Hyperuricemia or gout flare

Patients should be monitored regularly for blood pressure, renal function, and electrolyte balance.

• Blood pressure monitoring: check regularly to avoid hypotension.
• Renal function assessment: evaluate serum creatinine and eGFR before and during therapy.
• Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics.
• Caution in elderly: start at lower doses due to increased sensitivity.
• Avoid in severe liver disease: impaired metabolism may increase drug exposure.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid)

• Aliskiren (combined use with ARBs can increase renal risk).
• Potassium‑sparing diuretics or supplements (risk of hyperkalaemia).
• Lithium (increased lithium levels and toxicity).
• ACE inhibitors (additive effect on potassium and renal function).
• NSAIDs (may reduce antihypertensive efficacy and impair renal function).

Moderate Interactions (Monitor Closely)

• Other antihypertensives (potential additive hypotensive effect).
• Antidiabetic drugs (possible alteration of glucose control).
• Antimicrobials such as trimethoprim‑sulfamethoxazole (may affect potassium).
• Corticosteroids (enhance sodium retention).
• CYP2C9 inhibitors (may increase hydrochlorothiazide levels).